The Filing Desk

Personalis

PSNL · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

PSNL · Last close · November 13, 2026
$15.71
Value Personalis yourself

Personalis' revenue fell 17.7% to $70 million in fiscal 2025. Its operating margin was −126.4%, down from −80.7% a year earlier. Free cash flow was −$79 million. The diluted share count rose 50.6%.

Personalis, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076615 Updated
Revenue
$70M
17.7%
Operating margin
−126.4%
45.8 pts
Net income
−$81M
 
Free cash flow
−$79M
 
Return on equity
−35.0%
13.9 pts
Market cap
$1.7B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Personalis does

Personalis sells cancer genomic testing services. Doctors use its tests to look for leftover or returning cancer in patients, to follow how a cancer responds to treatment and to help choose therapies. Drug companies use its testing for research, for finding biomarkers (measurable signs of disease) and in clinical trials, including trials of personalized cancer therapies such as one run by Moderna.

The company says its technology is very sensitive and is focused on three uses: breast cancer, lung cancer and monitoring of immunotherapy. It works with cancer centers and universities to build clinical evidence and to win coverage from Medicare and other payers. In the fourth quarter of 2025 it received Medicare coverage for checking breast cancer recurrence.

Revenue comes from drug companies and from partners. It supplies tumor profiling to other diagnostics companies and has an agreement with Tempus to sell its NeXT Personal Dx test. It also does whole genome sequencing for the US Department of Veterans Affairs Million Veteran Program. Its revenue fell in 2025 as work for its largest enterprise customer, Natera, wound down. All of its lab work happens at a single facility.

Its biggest risks, as it describes them

  • A history of losses, with more expected and no assurance it will reach profitability.
  • A few customers account for a large share of its revenue.
  • Difficulty getting insurers to cover its tests and set rates that cover its costs.
  • Reliance on partners such as Tempus, Moderna and Merck, and on a few or single suppliers.
  • Having only one laboratory facility, so damage or loss of it could stop its services.
From Personalis's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Personalis lost money in fiscal 2025: a net loss of $81 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments287168114185240
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−355.2x−574.8x−999.4x−2,844.5x−429.6x
Current ratio10.2x6.0x3.1x6.5x6.8x
Quick ratio10.2x6.0x3.1x6.5x6.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Personalis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Personalis reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−78.4%−40.1%−131.8%
Altman Z''−5.75−0.990.31
Accruals ratio−20.1%−14.6%−2.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsPassPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Personalis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PersonalisFY25−17.7%−126.4%−114.1%———
PacBioFY253.9%−346.1%−71.2%−77.1%—3Compare
Ginkgo BioworksFY25−25.1%−185.3%−105.0%———Compare
CryoportFY2512.4%−20.9%−14.2%−23.4%—4Compare
Maravai LifeSciencesFY25−28.3%−115.9%−38.1%−32.0%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue93865798665748570
Revenue growth—302.1%72.6%20.6%8.7%−23.9%13.0%15.2%−17.7%
Gross profit−21222203213182716
Research and development101422294965654950
Operating income−22−14−22−42−65−116−110−68−88
Net income−24−20−25−41−65−113−108−81−81
Diluted EPS (US$)−7.78−6.49−1.39−1.20−1.49−2.48−2.25−1.37−0.91
Diluted shares (millions)3318344446485989
Cash flow
Cash from operations06−18−43−71−70−56−45−75
Capital expenditure588311501124
Free cash flow−5−2−26−46−82−120−67−47−79
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation1158141914119
Balance sheet at fiscal year end
Cash and short-term investments—20128203287168114185240
Debt incl. finance leases—————————
Total assets—42157245396293225270334
Total liabilities—5951508675966773
Shareholders' equity−93−106107195310218129203261
Margins and ratios
Gross margin−24.9%31.2%33.9%25.6%37.0%20.5%24.8%31.7%22.6%
Operating margin−235.9%−36.5%−34.4%−53.6%−76.4%−177.6%−149.6%−80.7%−126.4%
Net margin−251.2%−52.6%−38.5%−52.5%−76.3%−174.2%−147.4%−96.1%−116.7%
Free cash flow margin−51.8%−6.0%−40.6%−58.4%−95.8%−184.7%−91.4%−55.2%−114.1%
Rule of 40 (growth + FCF margin)—296.1%32.1%−37.8%−87.1%−208.6%−78.4%−40.1%−131.8%
Return on capital—————————
Return on equity———−27.4%−25.8%−42.9%−62.3%−48.9%−35.0%
Return on assets——−25.2%−20.5%−20.3%−32.9%−41.8%−32.8%−26.9%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Personalis' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Personalis.